Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
|Articles|September 14, 2018
Pharma Manufacturing Engages in Industry 4.0
Author(s)Pharmaceutical Technology Editors
New manufacturing and control technologies are being explored.
Advertisement
Industry 4.0-the paradigm of connecting physical systems by direct machine-to-machine communications via the Industrial Internet of Things-promises to improve efficiency, and companies across the pharmaceutical industry are embracing “digital transformation.” Merck, for example, seeks to connect “smart factories” for responsive and adaptive manufacturing (1). Pfizer is moving towards “connected manufacturing plants” that make data visible and available on demand (1). Sanofi is employing “digital twins” to simulate their biopharma manufacturing processes, as well as using collaborative robots, augmented reality, and paperless operations (1).
Learn more at CPhI WorldWide 2018, which will feature a Keynote Session Discussion panel on creating an Industry 4.0 Strategy for manufacturing.
References
1. J. Markarian,
Advertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement